拜瑞妥国内上市了吗？

Xarelto is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Xarelto is rapidly absorbed after oral administration. Peak concentration can be reached 2 to 4 hours after administration of 2.5 to 80 mg. It can be administered in multiple doses without accumulation within a reasonable range. It is eliminated in its original form by the kidneys and undergoes metabolic degradation. Multiple studies have shown that oral Xarelto has few interactions with food and drugs. It is currently a relatively safe and effective treatment method that does not require laboratory monitoring. Today let’s find out whether Xarelto has been launched in China?

Xarelto received marketing approval in Canada and the European Union on September 15 and October 1, 2008, respectively. Xarelto was approved for marketing by the State Food and Drug Administration in March 2009. In the same year, it was successfully included in the 2009 National Medical Insurance Directory. Approved by the FDA on July 1, 2011, the drug is used to prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery.

Xarelto is the world's first oral direct factor Xa inhibitor, which can highly selectively and competitively inhibit free and bound factor It has the characteristics of high bioavailability, wide spectrum of disease treatment, stable dose-effect relationship, convenient oral administration and low risk of bleeding.

The main clinical indications are: 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Indicated to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism. The recommended dose of Xarelto is 10 mg of oral rivaroxaban once daily. If the wound has stopped bleeding, the first medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.

The above is the content of Xarelto’s listing, I hope it can help you!